Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin

Cancer Research

Volumn 72, Issue 22, 2012, Pages 5824-5832

  Schmid, Jens O ^a   Dong, Meng ^a   Haubeiss, Silke ^a   Friedel, Godehard ^c   Bode, Sabine ^b   Grabner, Andreas ^b   Ott, German ^b   Mürdter, Thomas E ^a   Oren, Moshe ^d   Aulitzky, Walter E ^b   Van Der Kuip, Heiko ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c Klinik Schillerhohe   (Germany)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CELL ACTIVATION; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA DAMAGE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869237364     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1201     Document Type: Article

References (35)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-58.
2. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
3. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL, Espinosa JM. The p53 circuit board. Biochim Biophys Acta 2012;1825:229-44.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
5. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007;12:303-12.
6. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008.
7. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 2000;21:865-9.
8. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006;13:927-34.
9. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31.
10. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M Pafiti-Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 2005;65:1627-30.
11. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, et al. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 2010;70:9650-8.
12. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007;357:2543-51.
13. Wernert N, Löcherbach C, Wellmann A, Behrens P, Hügel A: Presence of genetic alterations in microdissected stroma of human colon and breast cancers. J Mol Med 2000;78:B30.
14. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
15. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008;40:650-5.
16. Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, et al. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer 2008;8:364.
17. Bar J, Feniger-Barish R, Lukashchuk N, Shaham H, Moskovits N, Gold finger N, et al. Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 2009;28:933-6.
18. van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006;6:86.
19. Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008;3:971-8.
20. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
21. Buschmann T, Minamoto T, Wagle N, Fuchs SY, Adler V, Mai M, et al. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. J Mol Biol 2000;295:1009-21.
22. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-44.
23. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A 2010;107:8352-6.
24. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010;75:173-234.
25. Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994;106 Suppl 6:377S-81S.
26. Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999;59:5572-7.
27. Kandioler-Eckersberger D, Kappel S, Mittlböck M, Dekan G, Ludwig C, Janschek E, et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:744-50
28. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72.
29. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, et al. Multiple stress signals activate mutant p53 in vivo. Cancer Res 2011;71:7168-75.
30. Wang JL, Jiao SC, Ye P, Li JY. P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:770-3.
31. Ebina M, Martínez A, Birrer MJ, Ilona Linnoila R. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers. Oncogene 2001;20:2579-86.
32. Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000;97:109-14.
33. Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, Krivokrysenko VI, et al. Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene 1998;17:1089-96.
34. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005;123:1001-11.
35. Dudley AC, Shih SC, Cliffe AR, Hida K, Klagsbrun M. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 2008;99:118-25.